RT Journal Article
SR Electronic
T1 <em>Schistosoma mansoni</em> infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.24.23284435
DO 10.1101/2023.02.24.23284435
A1 Muir, Roshell
A1 Metcalf, Talibah
A1 Fourati, Slim
A1 Bartsch, Yannic
A1 Lugemwa, Jacqueline Kyosiimire
A1 Canderan, Glenda
A1 Alter, Galit
A1 Muyanja, Enoch
A1 Okech, Brenda
A1 Namatovu, Teddy
A1 Namara, Irene
A1 Namuniina, Annemarie
A1 Ssetaala, Ali
A1 Mpendo, Juliet
A1 Nanvubya, Annet
A1 Kitandwe, Paul Kato
A1 Bagaya, Bernard S.
A1 Kiwanuka, Noah
A1 Nassuna, Jacent
A1 Biribawa, Victoria Menya
A1 Elliott, Alison M.
A1 de Dood, Claudia J.
A1 Senyonga, William
A1 Balungi, Priscilla
A1 Kaleebu, Pontiano
A1 Mayanja, Yunia
A1 Odongo, Mathew
A1 Fast, Pat
A1 Price, Matt A.
A1 Corstjens, Paul L.A.M.
A1 van Dam, Govert J.
A1 Kamali, Anatoli
A1 Sekaly, Rafick Pierre
A1 Haddad, Elias K
YR 2023
UL http://medrxiv.org/content/early/2023/02/26/2023.02.24.23284435.abstract
AB The impact of endemic infections on protective immunity is critical to inform vaccination strategies. In this study, we assessed the influence of Schistosoma mansoni infection on host responses in a Ugandan fishing cohort given a Hepatitis B (HepB) vaccine. Concentrations of schistosome-specific circulating anodic antigen (CAA) pre-vaccination showed a significant bimodal distribution associated with HepB titers, which were lower in individuals with high CAA. We established that participants with high CAA had significantly lower frequencies of circulating T follicular helper (cTfh) subpopulations pre- and post-vaccination and higher regulatory T cells (Tregs) post-vaccination. Polarization towards higher frequencies of Tregs: cTfh cells can be mediated by changes in the cytokine environment favoring Treg differentiation. In fact, we observed higher levels of CCL17 and soluble IL-2R pre-vaccination (important for Treg recruitment and development), in individuals with high CAA that negatively associated with HepB titers. Additionally, alterations in pre-vaccination monocyte function correlated with HepB titers, and changes in innate-related cytokines/chemokine production were associated with increasing CAA concentration. We report, that by influencing the immune landscape, schistosomiasis has the potential to modulate immune responses to HepB vaccination. These findings highlight multiple Schistosoma-related immune associations that could explain abrogated vaccine responses in communities with endemic infections.Author Summary Schistosomiasis drives host immune responses for optimal pathogen survival, potentially altering host responses to vaccine-related antigen. Chronic schistosomiasis and co-infection with hepatotropic viruses are common in countries where schistosomiasis is endemic. We explored the impact of Schistosoma mansoni (S. mansoni) infection on Hepatitis B (HepB) vaccination of individuals from a fishing community in Uganda. We demonstrate that high schistosome-specific antigen (circulating anodic antigen, CAA) concentration pre-vaccination, is associated with lower HepB antibody titers post-vaccination. We show higher pre-vaccination levels of cellular and soluble factors in instances of high CAA that are negatively associated with HepB antibody titers post-vaccination, which coincided with lower frequencies of circulating T follicular helper cell populations (cTfh), proliferating antibody secreting cells (ASCs), and higher frequencies of regulatory T cells (Tregs). We also show that monocyte function is important in HepB vaccine responses, and that high CAA is associated with alterations in the early innate cytokine/chemokine microenvironment. Our findings suggest that in individuals with high CAA and likely high worm burden, schistosomiasis creates and sustains an environment that is polarized against optimal host immune responses to the vaccine, which puts many endemic communities at risk for infection against HepB and other diseases that are preventable by vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Human Immune Project Consortium (HIPC) to EKH #U19 AI128910Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of UVRI-IAVI HIV Vaccine Program, Uganda Virus Research Institute, Entebbe gave ethical approval of this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors